Crinetics Pharmaceuticals prices offering at $45.95 per share

Crinetics Pharmaceuticals prices offering at $45.95 per share

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

New York, Jan 7, 2026, 11:04 EST — Regular session Shares of Crinetics Pharmaceuticals rose about 16% to $53.40 on Wednesday, after the biotech priced a $350 million stock offering and detailed early U.S. launch metrics for its newly approved acromegaly drug. Crinetics said it generated preliminary, unaudited net product revenue of more than $5 million from PALSONIFY in the fourth quarter of 2025, with more than 200 enrollment forms and over 125…

Crinetics Pharmaceuticals Announces $350 Million Public Offering Following Positive Phase II Results for CAH Drug

Crinetics Pharmaceuticals has announced a $350 million […] The post Crinetics Pharmaceuticals Announces $350 Million Public Offering Following Positive Phase II Results for CAH Drug first appeared on GeneOnline News. The post Crinetics Pharmaceuticals Announces $350 Million Public Offering Following Positive Phase II Results for CAH Drug appeared first on GeneOnline News.